KRAS and lung carcinoma: Initially, the screen was performed and validated on lung cancer cells whose viability depended on KRAS and subsequently, the top-scoring hit, i.e., USP39, was further validated in CRC cells, given that many of them are also dependent on mut-KRAS signaling.